idf europe ga meeting munich 2005 n.
Download
Skip this Video
Loading SlideShow in 5 Seconds..
IDF EUROPE GA MEETING MUNICH,2005 PowerPoint Presentation
Download Presentation
IDF EUROPE GA MEETING MUNICH,2005

Loading in 2 Seconds...

play fullscreen
1 / 13

IDF EUROPE GA MEETING MUNICH,2005 - PowerPoint PPT Presentation


  • 102 Views
  • Uploaded on

IDF EUROPE GA MEETING MUNICH,2005. SURVEY ON DIABETES CARE IN EIGHT CENTRAL EASTERN EUROPEAN COUNTRIES (THE DEPAC STUDY). Survey of diabetes care in eight new EU accessing countries.

loader
I am the owner, or an agent authorized to act on behalf of the owner, of the copyrighted work described.
capcha
Download Presentation

PowerPoint Slideshow about 'IDF EUROPE GA MEETING MUNICH,2005' - shantell-allen


An Image/Link below is provided (as is) to download presentation

Download Policy: Content on the Website is provided to you AS IS for your information and personal use and may not be sold / licensed / shared on other websites without getting consent from its author.While downloading, if for some reason you are not able to download a presentation, the publisher may have deleted the file from their server.


- - - - - - - - - - - - - - - - - - - - - - - - - - E N D - - - - - - - - - - - - - - - - - - - - - - - - - -
Presentation Transcript
idf europe ga meeting munich 2005
IDF EUROPE GA MEETINGMUNICH,2005

SURVEY ON DIABETES CARE

IN EIGHT CENTRAL EASTERN

EUROPEAN COUNTRIES

(THE DEPAC STUDY)

survey of diabetes care in eight new eu accessing countries
Survey of diabetes care in eight new EU accessing countries
  • Planned and organized by the Diabetes Experts’ Panel from Accessing Countries (DEPAC) established in May 2004
  • PROTOCOL

A multi-centre, randomised, non-interventional survey assessing metabolic control, short- and long term complications, and diabetes care of patients in 8 EU accessing countries

timelines of the survey critical milestones
Timelines of the survey(Critical milestones)
  • Preparations phase
  • Final protocol approved 22 Oct 2004
  • Translation of protocol into local languages 5 Nov
  • Investigators’ meetings in countries 19 Nov–17 Dec
  • Operations phase
  • Collection of data started 03 Jan 2005
  • Collection of data completed 28 Feb
  • Analysis phase
  • Statistical analysis complete 20 March
  • Integrated survey report complete (abstract to EASD) 28 March
number of patients planned 10 000 collected 11 085
Number of patients (planned:10 000; collected:11 085)

EST 200 HU 1800

LAT 300 CZ 2000

LIT 300 SLO300

SK 1100PL 4000

classification
CLASSIFICATION
  • Type 1 DM: 2497

22.85%

  • Type 2 DM: 8231

75.31%

  • Other Types of DM: 202

1.84%

age and diabetes duration
AGE AND DIABETES DURATION
  • Mean age (years):

Type 1 men:37,07 Type 2:61,08

women: 36,7063,17

  • Diabetes duration (years):

Type 1 men: 13,21 Type 2 :9,61

women: 14,3710,68

insulin treatment
INSULIN TREATMENT
  • Human insulins:

Type 1 DM: 70.10% Type 2 DM: 40.50%

  • Analog insulins:

Type 1 : 49.03% Type 2 : 10.82%

oral treatment
ORAL TREATMENT
  • Metformin Sulphonyloureas

Type 2 DM: 50.70%39.0%

  • AcarboseOral + Insulin

Type 2 : 10.0%14.20%

results metabolic control and lipids
Results: metabolic control and lipids
  • Poor metabolic control (HbA1c > 8%)

Type 1 DM: 49.10% Type 2 DM: 36.77%

  • Dyslipidemia (high serum lipids)

Type 1 : 29.03% Type 2 : 66.82%

results microvascular complications
Results: microvascular complications
  • Retinopathy

Type 1 : 41.30% Type 2 : 32.34%

  • Nephropathy

Type 1 : 28.46% Type 2 : 25.02%

  • Neuropathy

Type 1 : 31.79% Type 2 : 30.22%

results cardiovascular complications
Results: cardiovascular complications
  • Hypertension

Type 1 : 30.52% Type 2 : 79.49%

  • Cardiovascular disease

Type 1 : 8.58% Type 2 : 43.34%

survey analysis
SURVEY ANALYSIS

The only differences in diabetic complications between men and women which reached statistically significant levels were:

  • hypertension (P<0.01),
  • myocardial infarction (P<0.001),
  • peripheral arterial disease (P<0.001)
  • and diabetic foot ulcer (P<0.001)
conclusions
CONCLUSIONS

The results should be a platform for further goals

on country and EU levels:

  • highlighting the costs and benefits from diabetes treatment,
  • creating ways of health promotion and health monitoring,
  • increasing patient empowerment through education ,

- discussion about the status of National Diabetes Programmes in each countries.